ArticleReproductive biology and endocrinology : RB&E2009
A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.
Article in Reproductive biology and endocrinology : RB&E, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 61 citations in OpenAlex.
- The role of ERK-1 and ERK-2 gene polymorphisms in PCOS pathogenesis.Reproductive biology and endocrinology : RB&E · 2022Article
- The essential role of YAP in ERα36-mediated proliferation and the epithelial-mesenchymal transition in MCF-7 breast cancer cells.Frontiers in pharmacology · 2022Article
- Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors.International journal of molecular sciences · 2021Review
- ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by EstrogenFrontiers in oncology · 2021Article
- Estrogen Receptors and Estrogen-Induced Uterine Vasodilation in Pregnancy.International journal of molecular sciences · 2020Review
- The Role of ERα36 in Development and Tumor Malignancy.International journal of molecular sciences · 2020Review
- Bisphenol A induces human uterine leiomyoma cell proliferation through membrane-associated ERα36 via nongenomic signaling pathways.Molecular and cellular endocrinology · 2019Article
- Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- Tamoxifen enhances stemness and promotes metastasis of ERα36Cell research · 2018Article
- Short androgen receptor poly-glutamine-promoted endometrial cancer is associated with benzo[a]pyrene-mediated aryl hydrocarbon receptor activation.Journal of cellular and molecular medicine · 2018Article
- The expression of ER, PR in endometrial cancer and analysis of their correlation with ERK signaling pathway.Cancer biomarkers : section A of Disease markers · 2017Article
- ERα36, a variant of estrogen receptor α, is predominantly localized in mitochondria of human uterine smooth muscle and leiomyoma cells.PloS one · 2017Article
- The Role of Steroid Sulfatase as a Prognostic Factor in Patients with Endometrial Cancer.Yonsei medical journal · 2016Article
- Chaperone gp96 mediates ER-α36 cell membrane expression.Oncotarget · 2015Article
- Role of ER-α36 in breast cancer by typical xenoestrogens.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Estrogens and Male Lower Urinary Tract Dysfunction.Current urology reports · 2015Review
- High ERα36 Expression Level and Membrane Location Predict Poor Prognosis in Renal Cell Carcinoma.Medicine · 2015Observational
- The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors.Journal of translational medicine · 2014Review
- ER-α36: a novel biomarker and potential therapeutic target in breast cancer.OncoTargets and therapy · 2014Review
- Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer is one of the most common gynecologic malignancies and its incidence has recently increased. Experimental and epidemiological data support that testosterone plays an important role in the pathogenesis of endometrial cancer, but the underlying mechanism has not been fully understood. Recently, we identified and cloned a variant of estrogen receptor (ER) alpha, ER-alpha36. The aim of the present study was to investigate the role of ER-alpha36 in testosterone carcinogenesis.
methodsThe cellular localization of ER-alpha36 was determined by immunofluorescence. Hec1A endometrial cancer cells (Hec1A/V) and Hec1A cells with siRNA knockdown of ER-alpha36 (Hec1A/RNAi) were treated with testosterone, ERK and Akt phosphorylation was assessed by Western blot analysis. Furthermore, the kinase inhibitors U0126 and LY294002 and the aromatase inhibitor letrozole were used to elucidate the pathway underlying testosterone-induced activities.
resultsImmunofluorescence shows that ER-alpha36 was localized on the plasma membrane of the both ER-alpha- and androgen receptor-negative endometrial cancer Hec1A cells. Testosterone induced ERK and Akt phosphorylation, which could be abrogated by ER-alpha 36 shRNA knockdown or the kinase inhibitors, U0126 and LY294002, and the aromatase inhibitor letrozole.
conclusionTestosterone induces ERK and Akt phosphorylation via the membrane-initiated signaling pathways mediated by ER-alpha36, suggesting a possible involvement of ER-alpha 36 in testosterone carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.